1. MAPK/ERK Pathway
  2. Ribosomal S6 Kinase (RSK)

Ribosomal S6 Kinase (RSK)

Ribosomal S6 Kinase (RSK) is a family of protein kinases involved in signal transduction. There are two subfamilies of rsk, p90rsk, also known as MAPK-activated protein kinase-1 (MAPKAP-K1), and p70rsk, also known as S6-H1 Kinase or simply S6 Kinase. There are three variants of p90rsk in humans, rsk 1-3. Rsks are serine/threonine kinases and are activated by the MAPK/ERK pathway. There are two known mammalian homologues of S6 Kinase: S6K1 and S6K2. Rsk is named for ribosomal protein s6, part of the translational machinery, but several other substrates have been identified, including other ribosomal proteins. Cytosolic substrates of p90rsk include protein phosphatase 1; glycogen synthase kinase 3 (GSK3); L1 CAM, a neural cell adhesion molecule, the Ras exchange factor; and Myt1, an inhibitor of cdc2. p90rsk also regulates transcription factors including cAMP response element-binding protein (CREB); estrogen receptor-α (ERα); IκBα/NF-κB; and c-Fos.

Ribosomal S6 Kinase (RSK) Related Products (16):

Cat. No. Product Name Effect Purity
  • HY-10510
    BI-D1870 Inhibitor 99.21%
    BI-D1870 is a remarkably specific, ATP-competitive inhibitor of RSK isoforms, with IC50 values of 31 nM/24 nM/18 nM/15 nM for RSK1/SK2/SK3/SK4, respectively.
  • HY-52101
    CMK Inhibitor 99.53%
    CMK is a RSK2 kinase inhibitor, used for cancer treatment.
  • HY-15773
    PF-4708671 Inhibitor 99.81%
    PF-4708671 is a novel cell-permeable inhibitor of S6K1 (p70 ribosomal S6 kinase 1), with a Ki of 20 nM and IC50 of 160 nM.
  • HY-52101A
    FMK Inhibitor >98.0%
    FMK is a RSK2 kinase inhibitor.
  • HY-10579
    Pluripotin Inhibitor >98.0%
    Pluripotin (SC-1) inhibits in vitro kinase activity of RSK2 with EC50 of 2.5±1.8 μM.
  • HY-101963
    AD80 Inhibitor 99.46%
    AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
  • HY-12059
    AT7867 Inhibitor 99.74%
    AT7867 is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.
  • HY-12493A
    LY-2584702 tosylate salt Inhibitor 98.82%
    LY-2584702 tosylate salt is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.
  • HY-19713
    LJI308 Inhibitor 99.40%
    LJI308 is a new and potent pan-RSK inhibitor, with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
  • HY-16104
    BIX 02565 Inhibitor 98.48%
    BIX 02565 is a potent ribosomal S6 kinase 2 (RSK2) inhibitor with IC50 of 1.1 nM.
  • HY-19712
    LJH685 Inhibitor
    LJH685 is a potent , specific and selective RSK inhibitor, inhibits RSK1, 2, and 3 biochemical activities with IC50 of 4 to 13 nM.
  • HY-N0418
    Quercitrin Inhibitor 98.59%
    Quercitrin is a natural compound found in Tartary buckwheat with a potential anti-inflammation effect that is used to treat heart and vascular conditions.
  • HY-B0405A
    Bupivacaine hydrochloride Inhibitor 99.09%
    Bupivacaine Hydrochloride is a local anaesthetic drug belonging to the amino amide group.
  • HY-12493
    LY-2584702 free base Inhibitor 99.32%
    LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.
  • HY-12059A
    AT7867 dihydrochloride Inhibitor 99.56%
    AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.
  • HY-12493B
    LY-2584702 hydrochloride Inhibitor
    LY-2584702 Hcl is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.